KR20150138405A - 동물의 모발에 선택적으로 결합하는 항체 및 동물에 대한 항체 기재 약물 전달 시스템 - Google Patents

동물의 모발에 선택적으로 결합하는 항체 및 동물에 대한 항체 기재 약물 전달 시스템 Download PDF

Info

Publication number
KR20150138405A
KR20150138405A KR1020157033188A KR20157033188A KR20150138405A KR 20150138405 A KR20150138405 A KR 20150138405A KR 1020157033188 A KR1020157033188 A KR 1020157033188A KR 20157033188 A KR20157033188 A KR 20157033188A KR 20150138405 A KR20150138405 A KR 20150138405A
Authority
KR
South Korea
Prior art keywords
hair
antibody
binding
animal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157033188A
Other languages
English (en)
Korean (ko)
Inventor
스테판 호프만
한스-위르겐 함만
라이너 피셔
스테판 쉴베르크
시몬 올리버 보겔
헬가 쉰켈
Original Assignee
바이엘 인텔렉쳐 프로퍼티 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 인텔렉쳐 프로퍼티 게엠베하 filed Critical 바이엘 인텔렉쳐 프로퍼티 게엠베하
Publication of KR20150138405A publication Critical patent/KR20150138405A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A61K47/48369—
    • A61K47/48538—
    • A61K47/48876—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020157033188A 2007-11-02 2008-10-29 동물의 모발에 선택적으로 결합하는 항체 및 동물에 대한 항체 기재 약물 전달 시스템 Ceased KR20150138405A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07021396 2007-11-02
EP07021396.2 2007-11-02
PCT/EP2008/009110 WO2009056280A1 (en) 2007-11-02 2008-10-29 Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107012139A Division KR20100102103A (ko) 2007-11-02 2008-10-29 동물의 모발에 선택적으로 결합하는 항체 및 동물에 대한 항체 기재 약물 전달 시스템

Publications (1)

Publication Number Publication Date
KR20150138405A true KR20150138405A (ko) 2015-12-09

Family

ID=40157719

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157033188A Ceased KR20150138405A (ko) 2007-11-02 2008-10-29 동물의 모발에 선택적으로 결합하는 항체 및 동물에 대한 항체 기재 약물 전달 시스템
KR1020107012139A Ceased KR20100102103A (ko) 2007-11-02 2008-10-29 동물의 모발에 선택적으로 결합하는 항체 및 동물에 대한 항체 기재 약물 전달 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107012139A Ceased KR20100102103A (ko) 2007-11-02 2008-10-29 동물의 모발에 선택적으로 결합하는 항체 및 동물에 대한 항체 기재 약물 전달 시스템

Country Status (9)

Country Link
US (1) US20110263826A1 (https=)
EP (1) EP2207806B1 (https=)
JP (1) JP5386499B2 (https=)
KR (2) KR20150138405A (https=)
CN (1) CN101910198B (https=)
AU (1) AU2008317953B2 (https=)
CA (1) CA2704024C (https=)
NZ (1) NZ585004A (https=)
WO (1) WO2009056280A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2550863A1 (de) 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987161A (en) * 1974-06-19 1976-10-19 The Procter & Gamble Company Composition and method for conditioning hair with hair antiserum
BR9106124A (pt) * 1990-03-05 1992-12-01 Coopers Animal Health Composicao parasiticida para aplicacao topica e processo de controlar a infestacao de ectoparasitas em hospedeiros mamiferos,domesticos,nao humanos
JP2879947B2 (ja) * 1990-06-04 1999-04-05 鐘紡株式会社 毛髪改質剤
JPH06227955A (ja) * 1992-12-08 1994-08-16 Kanebo Ltd 染毛剤又は化粧料及び前処理剤並びに染毛方法
EP0673638A3 (en) * 1994-03-24 1996-10-16 Kao Corp Cosmetic composition containing antibodies.
US7067499B2 (en) * 2002-05-06 2006-06-27 Hercules Incorporated Cationic polymer composition and its use in conditioning applications

Also Published As

Publication number Publication date
CN101910198A (zh) 2010-12-08
EP2207806A1 (en) 2010-07-21
EP2207806B1 (en) 2013-04-10
KR20100102103A (ko) 2010-09-20
AU2008317953A1 (en) 2009-05-07
JP2011502178A (ja) 2011-01-20
CA2704024C (en) 2016-05-31
JP5386499B2 (ja) 2014-01-15
CA2704024A1 (en) 2009-05-07
WO2009056280A8 (en) 2010-06-10
AU2008317953B2 (en) 2014-03-20
CN101910198B (zh) 2014-10-29
US20110263826A1 (en) 2011-10-27
WO2009056280A1 (en) 2009-05-07
HK1151300A1 (en) 2012-01-27
NZ585004A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
JP6976847B2 (ja) 炎症及び自己免疫障害を治療するための抗ａｇｅ抗体
Li et al. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas
JP6018753B2 (ja) Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
ITRM990333A1 (it) Anticorpi monoclonali e suoi derivati sintetici o biotecnologici in grado di agire come molecole antagoniste per il ngf.
Asa et al. Fertility control in wildlife: Review of current status, including novel and future technologies
Lechat et al. Comparative evaluation of the prophylactic activity of a slow-release insecticide collar and a moxidectin spot-on formulation against Thelazia callipaeda infection in naturally exposed dogs in France
Bradley et al. Vaccines for fertility regulation of wild and domestic species
Adalid-Peralta et al. Understanding host–parasite relationship: the immune central nervous system microenvironment and its effect on brain infections
Esen et al. Modulation of connexin expression and gap junction communication in astrocytes by the gram‐positive bacterium S. aureus
KR102210112B1 (ko) 압타민 c를 유효성분으로 포함하는 동물의 탈모, 모발 손상 및 피부질환 개선 및 치료용 조성물
KR20110106943A (ko) 개선된-향의 살외부기생충 제제
US9273133B2 (en) Compositions and methods for the treatment and prevention of lens fibrotic diseases
KR20150138405A (ko) 동물의 모발에 선택적으로 결합하는 항체 및 동물에 대한 항체 기재 약물 전달 시스템
Malli et al. Quantifying the venom dose of the spider Cupiennius salei using monoclonal antibodies
KR20120095381A (ko) 액체 해충 구제 제제
Fayrer‐Hosken Controlling animal populations using anti‐fertility vaccines
Huang et al. Neuronal SNAP-23 is critical for synaptic plasticity and spatial memory independently of NMDA receptor regulation
JP2013136586A (ja) 血液脳関門を通したポリペプチドの非侵襲的な送達およびエンドサイトーシスリガンドの生体内選択
HK1151300B (en) Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals
Morales et al. Recombinant S3Pvac-phage anticysticercosis vaccine: Simultaneous protection against cysticercosis and hydatid disease in rural pigs
White A diagnostic approach to the pruritic horse
Fraser et al. Development of peptides for targeting cell ablation agents concurrently to the Sertoli and Leydig cell populations of the testes: An approach to non-surgical sterilization
CN109265549A (zh) 一种具有中和活性的抗人Tim-1抗体
McDowell et al. Application of pharmaceutical drug delivery for biological control of the common brushtail possum in New Zealand: a review
Miller et al. Immune mechanisms and characterization of injection site reactions involved in the multi-year contraceptive effect of the GonaCon™ vaccine

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151120

Application number text: 1020107012139

Filing date: 20100601

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151218

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160108

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170125

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160108

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I